Goldman Sachs: JD Health's performance in the first quarter exceeded expectations, raising its target price to 42.5 Hong Kong dollars.

Chinastar Financial APP has learned that Goldman Sachs has released a research report stating that it has raised its revenue forecast for JD Health (06618.HK) for the years 2025 to 2027 by an average of 2% to reflect strong sales of drugs and nutritional products exceeding expectations; considering that some of the gross profit margin growth will be offset by investments in self-distribution plans, the net profit forecast has been raised by 1 to 3%. The target price has been raised from HK$37.8 to HK$42.5, and the "buy" rating has been maintained.